Data Foundry

Drug recalls 2022

medroxyPROGESTERone Acetate Injectable Suspension — Class II drug recall D-1146-2022

Terminated recall by SUN PHARMACEUTICAL INDUSTRIES INC, reported 2022-06-22, distributed nationwide. Lack of assurance of sterility

Recall numberD-1146-2022
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmSUN PHARMACEUTICAL INDUSTRIES INC, Princeton, NJ, United States
Recall initiated2022-05-06
Classified2022-06-10
Reported by FDA2022-06-22
Terminated2023-08-14
DistributedNationwide (US)
Quantity180,813 syringes
Reason classessterility
NDC16714-0981-01
Lot numbersHAC0162A, HAC0163A, HAC0551A, HAC0562A, HAC1183A, HAC1184A, HAC1807A, HAC2075A, HAC2076A, HAC2077A, HAC2078A, HAC3803A, JKX6017A, JKX6018A
Expiration dates2022-12, 2023-01, 2023-02, 2023-03, 2023-04, 2023-06, 2023-07, 2023-08, 2023-09

Product

medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Single-Dose Vial, 150 mg/mL, Rx only, Manufactured for: Northstart Rx LLC, Memphis, TN, 38141, Manufactured by: Sun Pharmaceutical Industries Ltd., Halol Baroda Highway, Halol-389 350, Gujarat India , NDC 16714-981-01.

Reason for recall

Lack of assurance of sterility

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1146-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.